Meenakshi Mission Hospital and Research Centre | Clinical Research Department

Research site

(Unclaimed)

Location

Lake area, Melur Road, Madurai, Tamil Nadu, India

Site insights

Top conditions

Top treatments

Paclitaxel

Trastuzumab

BMS-986012

PF-05280014

BMS-986489

Pembrolizumab

Mezigdomide

zidebactam

Pomalidomide

Atezolizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 11 total trials

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo...

Enrolling

Carcinoma, Non-Small-Cell Lung

Drug: Placebo

Drug: Pemetrexed

Locations recently updated

A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with...

Enrolling

Extensive-Stage Small Cell Lung Cancer

Drug: Carboplatin

Biological: BMS-986489 (Atigotatug+Nivolumab)

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (SUCCESSOR-1)

The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide,...

Enrolling

Relapsed or Refractory Multiple Myeloma

Drug: Pomalidomide

Drug: mezigdomide

This is a Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ertapenem-zidebactam Versus Ceftazidime-Avibactam in the Treatment of Hospitalized Adult Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis

This is a Phase 2 randomized open label multicentre three arm comparative study evaluating the efficacy safety tolerability and pharmacokinetics of i...

Not yet enrolling

Acute Pyelonephritis

Complicated Urinary Tract Infections(cUTI)

Drug: Ertapenem-zidebactam

Drug: Ceftazidime-Avibactam